Status:
UNKNOWN
Chemoprevention of Esophageal Squamous Cell Carcinoma (ESCC) With Aspirin and Tea Polyphenols
Lead Sponsor:
Beijing Friendship Hospital
Conditions:
Carcinoma, Squamous Cell
Eligibility:
All Genders
40-60 years
Phase:
PHASE3
Brief Summary
Evidence from laboratory studies suggests that aspirin and tea polyphenols may have an antineoplastic effect in esophageal squamous cell carcinoma (ESCC). To assess the safety and efficacy of aspirin ...
Eligibility Criteria
Inclusion
- age 40 to 60 years;
- Lugol's chromoendoscopy showing at least one USL 1 cm or larger containing mild to moderate dysplasia and chronic inflammation;
- subject neither pregnant nor intending to become pregnant during the study.
Exclusion
- current non-steroidal anti-inflammatory drugs (NSAID) therapy;
- major intercurrent illness;
- pregnancy;
- invasive carcinoma;
- any condition that could be worsened by aspirin or tea polyphenols.
Key Trial Info
Start Date :
January 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2013
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT01496521
Start Date
January 1 2012
End Date
January 1 2013
Last Update
December 21 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Friendship Hospital Capital Medical University
Beijing, China, 100050